Salmonella synthesizing 1-monophosphorylated lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 412-423

  Kong, Qingke ^a   Six, David A ^b   Roland, Kenneth L ^a   Liu, Qing ^a   Gu, Lillian ^b   Reynolds, C Michael ^b   Wang, Xiaoyuan ^b   Raetz, Christian R H ^b   Curtiss III, Roy ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; INTERLEUKIN 17; INTERLEUKIN 6; LIVE VACCINE; MAGNESIUM ION; MEMBRANE PROTEIN; PHOSPHATIDATE PHOSPHATASE; SALMONELLA SYNTHESIZING 1 MONOPHOSPHORYLATED LIPOPOLYSACCHARIDE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CONTROLLED STUDY; DETOXIFICATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; IMMUNOGENICITY; INOCULATION; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SALMONELLOSIS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; CELL LINE, TUMOR; ENDOTOXINS; FEMALE; HUMANS; LIPID A; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; RABBITS; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, ATTENUATED;

EID: 79960405031     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100339     Document Type: Article

References (84)

1. Atkins, H. S., M. Morton, K. F. Griffin, M. G. M. Stokes, J. P. Nataro, and R. W. Titball. 2006. Recombinant Salmonella vaccines for biodefence. Vaccine 24: 2710-2717.
2. Lewis, G. K. 2007. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert Rev. Vaccines 6: 431-440. (Pubitemid 46911605)
3. Cheminay, C., and M. Hensel. 2008. Rational design of Salmonella recombinant vaccines. Int. J. Med. Microbiol. 298: 87-98.
4. Cárdenas, L., and J. D. Clements. 1992. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin. Microbiol. Rev. 5: 328-342.
5. Tacket, C. O., D. M. Hone, R. Curtiss, III, S. M. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect. Immun. 60: 536-541.
6. Tacket, C. O., M. B. Sztein, S. S. Wasserman, G. Losonsky, K. L. Kotloff, T. L. Wyant, J. P. Nataro, R. Edelman, J. Perry, P. Bedford, et al. 2000. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68: 1196-1201.
7. Rietschel, E. T., and C. Galanos. 1977. Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis. Infect. Immun. 15: 34-49.
8. Kong, W., S. Y. Wanda, X. Zhang, W. Bollen, S. A. Tinge, K. L. Roland, and R. Curtiss III. 2008. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc. Natl. Acad. Sci. USA 105: 9361-9366.
9. Raetz, C. R. H., and C. Whitfield. 2002. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71: 635-700.
10. Raetz, C. R. H., C. M. Reynolds, M. S. Trent, and R. E. Bishop. 2007. Lipid A modification systems in gram-negative bacteria. Annu. Rev. Biochem. 76: 295-329.
11. Miller, S. I., R. K. Ernst, and M. W. Bader. 2005. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 3: 36-46.
12. Lu, Y. C., W. C. Yeh, and P. S. Ohashi. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151.
13. Miyake, K. 2006. Roles for accessory molecules in microbial recognition by Toll-like receptors. J. Endotoxin Res. 12: 195-204. (Pubitemid 47470163)
14. Takeda, K., and S. Akira. 2004. TLR signaling pathways. Semin. Immunol. 16: 3-9.
15. Mata-Haro, V., C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell. 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
16. Kagan, J. C., T. Su, T. Horng, A. Chow, S. Akira, and R. Medzhitov. 2008. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferonbeta. Nat. Immunol. 9: 361-368.
17. Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805-820.
18. Rietschel, E. T., T. Kirikae, F. U. Schade, U. Mamat, G. Schmidt, H. Loppnow, A. J. Ulmer, U. Zähringer, U. Seydel, F. Di Padova, et al. 1994. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 8: 217-225. (Pubitemid 24067145)
19. Rietschel, E. T., T. Kirikae, F. U. Schade, A. J. Ulmer, O. Holst, H. Brade, G. Schmidt, U. Mamat, H. D. Grimmecke, S. Kusumoto, et al. 1993. The chemical structure of bacterial endotoxin in relation to bioactivity. Immunobiology 187: 169-190. (Pubitemid 23150766)
20. Park, B. S., D. H. Song, H. M. Kim, B. S. Choi, H. Lee, and J. O. Lee. 2009. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
21. Erridge, C., E. Bennett-Guerrero, and I. R. Poxton. 2002. Structure and function of lipopolysaccharides. Microbes Infect. 4: 837-851.
22. Reed, S. G., S. Bertholet, R. N. Coler, and M. Friede. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30: 23-32.
23. Baldridge, J. R., and R. T. Crane. 1999. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19: 103-107.
24. Wheeler, A. W., J. S. Marshall, and J. T. Ulrich. 2001. ATh1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 126: 135-139.
25. Vernacchio, L., H. Bernstein, S. Pelton, C. Allen, K. MacDonald, J. Dunn, D. D. Duncan, G. Tsao, V. LaPosta, J. Eldridge, et al. 2002. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 20: 3658-3667. (Pubitemid 35223395)
26. Thompson, B. S., P. M. Chilton, J. R. Ward, J. T. Evans, and T. C. Mitchell. 2005. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 78: 1273-1280.
27. Wang, X. Y., M. J. Karbarz, S. C. McGrath, R. J. Cotter, and C. R. H. Raetz. 2004. MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of Francisella novicida LpxE expressed in Escherichia coli. J. Biol. Chem. 279: 49470-49478.
28. Bertani, G. 1951. Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli. J. Bacteriol. 62: 293-300.
29. Shi, Y. X., T. Latifi, M. J. Cromie, and E. A. Groisman. 2004. Transcriptional control of the antimicrobial peptide resistance ugtL gene by the Salmonella PhoP and SlyA regulatory proteins. J. Biol. Chem. 279: 38618-38625.
30. + expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Nat. Biotechnol. 6: 693-697.
31. Neidhardt, F. C., P. L. Bloch, and D. F. Smith. 1974. Culture medium for enterobacteria. J. Bacteriol. 119: 736-747.
32. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
33. Hassan, J. O., and R. Curtiss III. 1990. Control of colonization by virulent Salmonella typhimurium by oral immunization of chickens with avirulent delta cya delta crp S. typhimurium. Res. Microbiol. 141: 839-850.
34. Edwards, R. A., L. H. Keller, and D. M. Schifferli. 1998. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 207: 149-157.
35. Roland, K., R. Curtiss, III, and D. Sizemore. 1999. Construction and evaluation of a delta cya delta crp Salmonella typhimurium strain expressing avian pathogenic Escherichia coli O78 LPS as a vaccine to prevent airsacculitis in chickens. Avian Dis. 43: 429-441. (Pubitemid 29437618)
36. Hitchcock, P. J., and T. M. Brown. 1983. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J. Bacteriol. 154: 269-277.
37. 2+ environments. J. Bacteriol. 179: 7040-7045.
38. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
39. Gibbons, H. S., C. M. Reynolds, Z. Q. Guan, and C. R. H. Raetz. 2008. An inner membrane dioxygenase that generates the 2-hydroxymyristate moiety of Salmonella lipid A. Biochemistry 47: 2814-2825.
40. Yi, E. C., and M. Hackett. 2000. Rapid isolation method for lipopolysaccharide and lipid A from gram-negative bacteria. Analyst (Lond.) 125: 651-656.
41. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J. Immunol. 165: 618-622.
42. Osborn, M. J. 1963. Studies on gram-negative cell wall. 1. evidence for role of 2-Keto-3-deoxyoctonate in Lipopolysaccharide of Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 50: 499-506.
43. Kang, H. Y., J. Srinivasan, and R. Curtiss III. 2002. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect. Immun. 70: 1739-1749.
44. Xin, W., S. Y. Wanda, Y. Li, S. Wang, H. Mo, and R. Curtiss III. 2008. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect. Immun. 76: 3241-3254.
45. Li, Y., S. Wang, W. Xin, G. Scarpellini, Z. Shi, B. Gunn, K. L. Roland, and R. Curtiss III. 2008. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect. Immun. 76: 5238-5246.
46. Briles, D. E., J. D. King, M. A. Gray, L. S. McDaniel, E. Swiatlo, and K. A. Benton. 1996. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 14: 858-867.
47. Nayak, A. R., S. A. Tinge, R. C. Tart, L. S. McDaniel, D. E. Briles, and R. Curtiss III. 1998. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect. Immun. 66: 3744-3751.
48. Zhou, Z. M., S. H. Lin, R. J. Cotter, and C. R. H. Raetz. 1999. Lipid A modifications characteristic of Salmonella typhimurium are induced by NH4VO3 in Escherichia coli K12. Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate. J. Biol. Chem. 274: 18503-18514.
49. Gibbons, H. S., S. R. Kalb, R. J. Cotter, and C. R. H. Raetz. 2005. Role of Mg2+ and pH in the modification of Salmonella lipid A after endocytosis by macrophage tumour cells. Mol. Microbiol. 55: 425-440.
50. Bader, M. W., S. Sanowar, M. E. Daley, A. R. Schneider, U. S. Cho, W. Q. Xu, R. E. Klevit, H. Le Moual, and S. I. Miller. 2005. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 122: 461-472.
51. Bader, M. W., W. W. Navarre, W. Shiau, H. Nikaido, J. G. Frye, M. McClelland, F. C. Fang, and S. I. Miller. 2003. Regulation of Salmonella typhimurium virulence gene expression by cationic antimicrobial peptides. Mol. Microbiol. 50: 219-230.
52. 2+ as an extracellular signal: environmental regulation of Salmonella virulence. Cell 84: 165-174.
53. Kong, Q., Q. Liu, K. L. Roland, and R. Curtiss III. 2009. Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect. Immun. 77: 5572-5582.
54. Belden, W. J., and S. I. Miller. 1994. Further characterization of the PhoP regulon: identification of new PhoP-activated virulence loci. Infect. Immun. 62: 5095-5101.
55. Coulson, N. M., M. Fulop, and R. W. Titball. 1994. Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent Salmonella typhimurium SL 3261. Microb. Pathog. 16: 305-311.
56. Valentine, P. J., B. P. Devore, and F. Heffron. 1998. Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant. Infect. Immun. 66: 3378-3383.
57. Bumann, D. 2001. Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses. Infect. Immun. 69: 7493-7500.
58. Ramarathinam, L., D. W. Niesel, and G. R. Klimpel. 1993. Salmonella typhimurium induces IFN-gamma production in murine splenocytes. Role of natural killer cells and macrophages. J. Immunol. 150: 3973-3981.
59. Chan, S., and V. N. Reinhold. 1994. Detailed structural characterization of lipid A: electrospray ionization coupled with tandem mass spectrometry. Anal. Biochem. 218: 63-73.
60. Morrison, D. C., R. Silverstein, M. Luchi, and A. Shnyra. 1999. Structurefunction relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect. Dis. Clin. North Am. 13: 313-340.
61. Garçon, N., P. Chomez, and M. Van Mechelen. 2007. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6: 723-739. (Pubitemid 47607848)
62. Beckwith, J. R., E. R. Signer, and W. Epstein. 1966. Transposition of the Lac region of E. coli. Cold Spring Harb. Symp. Quant. Biol. 31: 393-401.
63. Schmid, M. B., and J. R. Roth. 1987. Gene location affects expression level in Salmonella typhimurium. J. Bacteriol. 169: 2872-2875.
64. Sztein, M. B., S. S. Wasserman, C. O. Tacket, R. Edelman, D. Hone, A. A. Lindberg, and M. M. Levine. 1994. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170: 1508-1517.
65. Keuter, M., E. Dharmana, M. H. Gasem, J. van der Ven-Jongekrijg, R. Djokomoeljanto, W. M. V. Dolmans, P. Demacker, R. Sauerwein, H. Gallati, and J. W. M. van der Meer. 1994. Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J. Infect. Dis. 169: 1306-1311.
66. Evans, J. T., C. W. Cluff, D. A. Johnson, M. J. Lacy, D. H. Persing, and J. R. Baldridge. 2003. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2: 219-229.
67. Eperon, S., D. De Groote, G. Werner-Felmayer, and T. W. Jungi. 1997. Human monocytoid cell lines as indicators of endotoxin: comparison with rabbit pyrogen and Limulus amoebocyte lysate assay. J. Immunol. Methods 207: 135-145.
68. Kawasaki, K., R. K. Ernst, and S. I. Miller. 2004. Deacylation and palmitoylation of lipid A by Salmonellae outer membrane enzymes modulate host signaling through Toll-like receptor 4. J. Endotoxin Res. 10: 439-444.
69. Montminy, S. W., N. Khan, S. McGrath, M. J.Walkowicz, F. Sharp, J. E. Conlon, K. Fukase, S. Kusumoto, C. Sweet, K. Miyake, et al. 2006. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 7: 1066-1073.
70. Sun, W., D. Six, X. Kuang, K. L. Roland, C. R. H. Raetz, and R. Curtiss III. 2011. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine 29: 2986-2998.
71. Haraga, A., M. B. Ohlson, and S. I. Miller. 2008. Salmonellae interplay with host cells. Nat. Rev. Microbiol. 6: 53-66.
72. Khan, S. A., P. Everest, S. Servos, N. Foxwell, U. Zähringer, H. Brade, E. T. Rietschel, G. Dougan, I. G. Charles, and D. J. Maskell. 1998. A lethal role for lipid A in Salmonella infections. Mol. Microbiol. 29: 571-579.
73. Low, K. B., M. Ittensohn, T. Le, J. Platt, S. Sodi, M. Amoss, O. Ash, E. Carmichael, A. Chakraborty, J. Fischer, et al. 1999. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 17: 37-41.
74. Pasetti, M. F., J. K. Simon, M. B. Sztein, and M. M. Levine. 2011. Immunology of gut mucosal vaccines. Immunol. Rev. 239: 125-148.
75. Ameiss, K., S. Ashraf, W. Kong, A. Pekosz, W. H. Wu, D. Milich, J. N. Billaud, and R. Curtiss III. 2010. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine 28: 6704-6713.
76. Gilman, R. H., R. B. Hornick, W. E. Woodard, H. L. DuPont, M. J. Snyder, M. M. Levine, and J. P. Libonati. 1977. Evaluation of a UDP-glucose-4- epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J. Infect. Dis. 136: 717-723.
77. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173: 1408-1414.
78. Tran, T. H., T. D. Nguyen, T. T. Nguyen, T. T. Ninh, N. B. Tran, V. M. Nguyen, T. T. Tran, T. T. Cao, V. M. Pham, T. C. Nguyen, et al. 2010. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS ONE 5: e11778.
79. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65: 452-456.
80. Curtiss, R., III, W. Xin, Y. H. Li, W. Kong, S. Y. Wanda, B. Gunn, and S. F. Wang. 2010. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit. Rev. Immunol. 30: 255-270.
81. Wang, S. F., Y. H. Li, G. Scarpellini, W. Kong, H. Y. Shi, C. H. Baek, B. Gunn, S. Y. Wanda, K. L. Roland, X. Zhang, et al. 2010. Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity. Infect. Immun. 78: 3969-3980.
82. Hindle, Z., S. N. Chatfield, J. Phillimore, M. Bentley, J. Johnson, C. A. Cosgrove, M. Ghaem-Maghami, A. Sexton, M. Khan, F. R. Brennan, et al. 2002. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 70: 3457-3467.
83. Curtiss, R., III, S.-Y. Wanda, B. M. Gunn, X. Zhang, S. A. Tinge, V. Ananthnarayan, H. Mo, S. Wang, and W. Kong. 2009. Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect. Immun. 77: 1071-1082.
84. Levine, M. M. 2009. Typhoid vaccines ready for implementation. N. Engl. J. Med. 361: 403-405.